EP1008343A1 - Rapidly soluble filmy preparation - Google Patents
Rapidly soluble filmy preparation Download PDFInfo
- Publication number
- EP1008343A1 EP1008343A1 EP98945623A EP98945623A EP1008343A1 EP 1008343 A1 EP1008343 A1 EP 1008343A1 EP 98945623 A EP98945623 A EP 98945623A EP 98945623 A EP98945623 A EP 98945623A EP 1008343 A1 EP1008343 A1 EP 1008343A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- rapidly soluble
- film preparation
- soluble film
- weight
- film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Definitions
- the present invention relates to a film preparation (film-shaped drug) rapidly soluble in the oral cavity, and more particularly to a rapidly soluble film preparation for oral administration containing a saccharide in a base, for the purpose of allowing a drug to be mainly absorbed into the digestive organs by rapidly dissolving the drug in the oral cavity.
- the preparations for oral application include buccal tablets and mucosa-adhesive film preparations.
- these are ones in which the drugs are allowed to be absorbed through the mucous membranes in the oral cavity, or ones for the purpose of treatment of diseases in the oral cavity, and are not ones for the purpose of usual drug absorption into the digestive tracts. Almost all of these are contrived to continuously release the drugs, and no rapidly soluble ones have been known.
- a sheet-shaped administration formation such as medicine, confectionery, other food, a cosmetic or an article similar thereto orally administered or incorporated, which comprises 20 to 60% by weight of at least one film forming agent, 2 to 40% by weight of at least one gel forming agent, 0.1 to 35% by weight of at least one active substance (drug) and further less than 40% by weight of at least one inactive filler, and rapidly decomposes in water (Toku-Kai-Hei (Japanese Unexamined Patent Publication) 7-100186), and (B) a tape having a tensile strength of at least 200 psi (about 14 kg/cm 2 ), a drug/mm 3 of 0.01 to 2 mg and an optimum solubility to the drug, and having a composition comprising about 10 to 40% by weight
- (C) a sheet-shaped solid pharmaceutical composition characterized in that a solution or a suspension containing a substance having physiologically active action by the existence thereof in slight amounts is printed on, spread on, sprayed on, or injected into a pharmaceutically acceptable sheet-shaped carrier (Toku-Kai-Hei 5-124954) is also known.
- sorbitol lubricant
- a disintegrating agent for example, cross caramelose Na type A
- cross caramelose Na type A can be used in an amount of not exceeding about 10% by weight
- the drug tape is mounted on a dispenser, so that it is necessary to have a definite tensile strength. Control for the tensile strength is therefore required in production, which is disadvantageous to efficiency in actual production.
- the substance showing physiologically activity by the existence thereof in slight amounts (a drug: for example, 0.02 mg per unit, in the case of mestranol) is utilized.
- the drug is effectively used in such slight amounts, so that the solution or suspension of the drug is printed on, spread on, sprayed on, or injected into the sheet-shaped carrier.
- this is time-consuming and not economical.
- punching is performed with a punch, resulting in complication of the process.
- An object of the invention is to economically provide a film preparation having no disadvantages observed in the above-mentioned known film preparations, that is to say, rapidly dissolved, simply produced and economically obtained.
- the present inventors have variously studied for obtaining a film preparation having sufficient rapid solubility by a simple process by the addition of one ingredient. As a result, the present inventors have discovered that the use of a drug, an edible polymer and a monosaccharide, a sugar alcohol or an oligosaccharide in combination can solve the above-mentioned problems, thus completing the present invention.
- the present invention relates to (1) a rapidly soluble film preparation mainly comprising a drug, an edible polymer and a saccharide, (2) the rapidly soluble film preparation described in (1), in which the content of the drug is from 0.01 to 50% by weight, that of the edible polymer is from 20 to 90% by weight, and that of the saccharide is from 1 to 50% by weight, (3) the rapidly soluble film preparation described in (1), in which the drug is a compound enhanced in internal absorption by the conversion to a solid solution, (4) the rapidly soluble film preparation described in (3), in which the compound enhanced in internal absorption by the conversion to the solid solution is nilvadipine, (5) the rapidly soluble film preparation described in (1), in which the edible polymer is one selected from the group consisting of synthetic polymers, cellulose derivatives and natural polymers, (6) the rapidly soluble film preparation described in (1) or (5), in which the edible polymer is at least one selected from the group consisting of poly(vinylpyrrolidone), hydroxypropyl methyl cellulose
- the film preparation of the invention is characterized in that it is rapidly dissolved in the oral cavity and can be taken without water, as a dosage form substitutive for a tablet.
- the invention is the rapidly soluble film preparation in which the drug is allowed to be contained in a film base comprising the edible polymer such as poly (vinylpyrrolidone), hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxyethyl cellulose or ethyl cellulose, and the monosaccharide, the sugar alcohol or the oligosaccharide, and which is easily produced and has no conventional disadvantages as described above.
- the edible polymer such as poly (vinylpyrrolidone), hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxyethyl cellulose or ethyl cellulose, and the monosaccharide, the sugar alcohol or the oligosaccharide, and which is easily produced and has no conventional disadvantages as described above.
- the saccharides used in the invention include sugar alcohols such as erythritol, pentitol and hexitol, monosaccharides (aldose and ketose) and oligosaccharides.
- sugar alcohols include xylitol, mannitol, D-sorbitol and reducing maltose starch syrup
- the monosaccharides include glucose and fructose
- the oligosaccharides include maltose, lactose and sucrose
- the monosaccharide-oligosaccharides include starch syrup. Reducing maltose starch syrup is particularly preferred.
- the compounding amount of the saccharides in the film preparation of the present invention is from 1 to 50% by weight, and preferably from 5 to 50% by weight. Less than 1% results in the insufficient rate of dissolution, whereas exceeding 50% raises a problem with regard to the shape retaining property of products, although the rate of dissolution is increased.
- Many of the saccharides have sweet tastes, and this is advantageous for the film preparations soluble in the mouth. Further, many of them also act as plasticizers, like starch syrup. Accordingly, when they are used, it is not necessary to especially use plasticizers. Of course, the plasticizers may be used as so desired. When sorbitol is used as the saccharide, sorbitol sometimes deposits as crystallites on film surfaces. However, the drug effect and the others are not affected at all.
- the edible polymer which is a component of the film base of the invention, as long as it has film forming ability and is edible.
- the edible polymers include synthetic polymers, for example, poly(vinylpyrrolidone) (hereinafter described as "PVP"), carboxyvinyl polymers (hereinafter described as “CVPs”), polyvinyl alcohol (hereinafter described as “PVA”) and the like, cellulose derivatives, such as hydroxypropyl methyl cellulose (hereinafter described as "HPMC”), hydroxypropyl cellulose (hereinafter described as "HPC”), hydroxyethyl cellulose (hereinafter described as "HEC”), methyl cellulose (hereinafter described as “MC”), ethyl cellulose (hereinafter described as “EC”) and the like, and polymers obtained from natural products, for example, sodium alginate, dextran, casein, pullulan and the like. Particularly preferred are PVP and HPC. These substances can be used either alone or as
- the total compounding amount of the edible polymers in the film preparation is from 20 to 90% by weight, and preferably from 25 to 80% by weight in all.
- aromatics, coloring matter, preservatives, antioxidants, stabilizing agents, surfactants, plasticizers and the like may be properly used as components of the film bases, as so desired, in addition to the above-mentioned substances.
- drugs used in the invention there is no particular limitation on the drugs used in the invention, as long as they can be orally administered.
- Specific examples thereof include calcium antagonists such as nilvadipine and nicardipine, ⁇ 2-stimulants such as procaterol hydrochloride and fenoterol hydrobromide, oral antidiabetic drugs such as glibenclamide, somniferous drugs such as brotizolam and triazolam, ⁇ -blockers such as arotinolol hydrochloride and carteolol hydrochloride, therapeutic drugs for the coronary vessels such as nicorandil, anesthetics such as dibucaine hydrochloride, nonsteroidal anti-inflammatory drugs such as diclofenac sodium and indomethacin, and sedatives such as diphenhydramine hydrochloride and scopolamine hydrobromide.
- calcium antagonists such as nilvadipine and nicardipine
- ⁇ 2-stimulants such as procate
- the drugs used in the invention ones having no bitter tastes are suitable. However, even ones having bitter tastes can be used in the invention by masking such as microcapsulation.
- the compounding amount of the drugs in the film preparation is usually from 1 to 50% by weight, although it varies depending on the properties of the drugs.
- the rapidly soluble film preparations of the invention are produced, for example, by the following method.
- Specified amounts of the edible polymer, saccharide and drug are dissolved in a solvent in which these substances are soluble, for example, ethanol, and the resulting solution is spread on a liner film and dried to obtain a film.
- the film is cut to a desired size, and hermetically packaged if necessary to provide a product.
- the dissolution of the drug can be accelerated by heating to about 50 to about 60°C in preparing the solution. Further, when foams are developed in the solution in preparing it, standing overnight or vacuum deaeration is preferably conducted.
- the solvent used in preparing the solution as long as it dissolves the respective compounding components. Either a single solvent or a combined solvent may be used.
- the solvents include ethanol, a mixture of ethanol and water, and the like.
- the specified edible polymers are used, some kinds of drugs are enhanced in internal absorption thereof. That is to say, for example, when the drug is nilvadipine, the use of poly(vinylpyrrolidone) and/or hydroxypropyl methyl cellulose as the edible polymer(s) enhances the internal absorption. This is considered to be caused by the formation of a good solid solution by nilvadipine with these polymers.
- the film preparation can be produced by the use of only poly(vinylpyrrolidone) and/or hydroxypropyl methyl cellulose as the edible polymer(s), but an additional edible polymer can provide a better film preparation.
- nilvadipine hydroxypropyl cellulose is suitably used.
- drugs forming the solid solutions with the edible polymers include nifedipine, phenytoin, chloramphenicol, griseofulvin, sulfamethizole and the like, as well as nilvadipine.
- nilvadipine 76.0 parts by weight of HPC and 20.0 parts by weight of reducing maltose starch syrup were added and dissolved by stirring. This was spread on a polyester liner film and dried to produce a film having a thickness of about 250 ⁇ m. The resulting film was cut to a square, 16 mm each side, thereby obtaining a film preparation rapidly soluble in the oral cavity.
- nilvadipine 72.0 parts by weight of HPC, 4.0 parts by weight of PVP and 20.0 parts by weight of reducing maltose starch syrup were added and dissolved by stirring. This was spread on a polyester liner film and dried to produce a film having a thickness of about 250 ⁇ m. The resulting film was cut to a square, 16 mm each side, thereby obtaining a film preparation rapidly soluble in the oral cavity.
- nicardipine hydrochloride 20.0 parts by weight of nicardipine hydrochloride, 40.0 parts by weight of HPC, 20.0 parts by weight of PVP and 20.0 parts by weight of reducing maltose starch syrup were added and dissolved by stirring. This was spread on a polyester liner film and dried to produce a film having a thickness of about 250 ⁇ m. The resulting film was cut to a square, 16 mm each side, thereby obtaining a film preparation rapidly soluble in the oral cavity.
- nilvadipine 76.0 parts by weight of HPC and 20.0 parts by weight of PVP were added and dissolved by stirring. This was spread on a polyester liner film and dried to produce a film having a thickness of about 250 ⁇ m. The resulting film was cut to a square, 16 mm each side, thereby obtaining a film preparation rapidly soluble in the oral cavity.
- the film preparations of the invention are very easily produced, have high rapid solubility, are extremely high in practical use, and are suitable for using as film preparations for oral administration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
- The present invention relates to a film preparation (film-shaped drug) rapidly soluble in the oral cavity, and more particularly to a rapidly soluble film preparation for oral administration containing a saccharide in a base, for the purpose of allowing a drug to be mainly absorbed into the digestive organs by rapidly dissolving the drug in the oral cavity.
- At present, as the drugs orally administered, naked tablets, coated tablets, capsules, powders, granules, pills and aqueous drugs (solutions) have been put on the market. Then, the preparations for oral application include buccal tablets and mucosa-adhesive film preparations. However, these are ones in which the drugs are allowed to be absorbed through the mucous membranes in the oral cavity, or ones for the purpose of treatment of diseases in the oral cavity, and are not ones for the purpose of usual drug absorption into the digestive tracts. Almost all of these are contrived to continuously release the drugs, and no rapidly soluble ones have been known.
- Drugs commercially available as merely film-shaped, tape-shaped or sheet-shaped ones, not adhesive to the mucous membranes in the oral cavity, are not found. However, as seen from documents (patents), (A) a sheet-shaped administration formation such as medicine, confectionery, other food, a cosmetic or an article similar thereto orally administered or incorporated, which comprises 20 to 60% by weight of at least one film forming agent, 2 to 40% by weight of at least one gel forming agent, 0.1 to 35% by weight of at least one active substance (drug) and further less than 40% by weight of at least one inactive filler, and rapidly decomposes in water (Toku-Kai-Hei (Japanese Unexamined Patent Publication) 7-100186), and (B) a tape having a tensile strength of at least 200 psi (about 14 kg/cm2), a drug/mm3 of 0.01 to 2 mg and an optimum solubility to the drug, and having a composition comprising about 10 to 40% by weight of a physiologically acceptable thermoplastic polymer, about 15 to 50% by weight of a saccharide, about 5 to 40% by weight of a physiologically acceptable plasticizer and about 0 to 20% by weight of a physiologically acceptable lubricant (Toku-Kai-Hei 5-220203) are known. Further, (C) a sheet-shaped solid pharmaceutical composition characterized in that a solution or a suspension containing a substance having physiologically active action by the existence thereof in slight amounts is printed on, spread on, sprayed on, or injected into a pharmaceutically acceptable sheet-shaped carrier (Toku-Kai-Hei 5-124954) is also known.
- However, in the above-mentioned invention (A), it is described that "it is an object of this invention to provide an administration formation rapidly decomposing in water and individually formulated in a sheet form" (the publication, page 8, right column, [0028]), but what contrivance causes the formation to rapidly decompose is not described at all. Although a drug is obtained in Example 2, merely "the drug decomposes in the mouth" (the publication,
page 10, left column, [0064]) is only described, and details such as for the time for decomposition of the drug decomposes are not clear. In this Example 2, the temperature is elevated to 80°C in preparation, so that a considerable period of time is taken for cooling after mixing and the like, which causes a disadvantage in the manufacturing process. Further, in the above-mentioned invention (B), sorbitol (lubricant) is used as one useful to enhance speeds of disintegration and dissolution of the tape. However, it is described that "for further assisting dissolution, a disintegrating agent, for example, cross caramelose Na type A, can be used in an amount of not exceeding about 10% by weight", and this is considered because the use of only sorbitol sometimes results in an insufficient disintegration rate. Furthermore, in this invention, the drug tape is mounted on a dispenser, so that it is necessary to have a definite tensile strength. Control for the tensile strength is therefore required in production, which is disadvantageous to efficiency in actual production. Still further, in the above-mentioned invention (C), the substance showing physiologically activity by the existence thereof in slight amounts (a drug: for example, 0.02 mg per unit, in the case of mestranol) is utilized. The drug is effectively used in such slight amounts, so that the solution or suspension of the drug is printed on, spread on, sprayed on, or injected into the sheet-shaped carrier. However, this is time-consuming and not economical. Then, with respect to one shown in Fig. 1 of the published specification, not only slights are provided, but also punching is performed with a punch, resulting in complication of the process. - An object of the invention is to economically provide a film preparation having no disadvantages observed in the above-mentioned known film preparations, that is to say, rapidly dissolved, simply produced and economically obtained.
- The present inventors have variously studied for obtaining a film preparation having sufficient rapid solubility by a simple process by the addition of one ingredient. As a result, the present inventors have discovered that the use of a drug, an edible polymer and a monosaccharide, a sugar alcohol or an oligosaccharide in combination can solve the above-mentioned problems, thus completing the present invention.
- That is to say, the present invention relates to (1) a rapidly soluble film preparation mainly comprising a drug, an edible polymer and a saccharide, (2) the rapidly soluble film preparation described in (1), in which the content of the drug is from 0.01 to 50% by weight, that of the edible polymer is from 20 to 90% by weight, and that of the saccharide is from 1 to 50% by weight, (3) the rapidly soluble film preparation described in (1), in which the drug is a compound enhanced in internal absorption by the conversion to a solid solution, (4) the rapidly soluble film preparation described in (3), in which the compound enhanced in internal absorption by the conversion to the solid solution is nilvadipine, (5) the rapidly soluble film preparation described in (1), in which the edible polymer is one selected from the group consisting of synthetic polymers, cellulose derivatives and natural polymers, (6) the rapidly soluble film preparation described in (1) or (5), in which the edible polymer is at least one selected from the group consisting of poly(vinylpyrrolidone), hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxyethyl cellulose and ethyl cellulose, (7) the rapidly soluble film preparation described in (1) or (2), in which the saccharide is one selected from the group consisting of monosaccharides, sugar alcohols and oligosaccharides, (8) the rapidly soluble film preparation described in (7), in which the oligosaccharide is starch syrup, (9) the rapidly soluble film preparation described in (8), in which the starch syrup is reducing maltose starch syrup, (10) the rapidly soluble film preparation described in (1), in which the drug is a compound which can be enhanced in internal absorption by the conversion to a solid solution, the edible polymer is one or more of poly(vinyl-pyrrolidone) and hydroxypropyl cellulose, and an additional edible polymer, and the saccharide is starch syrup, and (11) the rapidly soluble film preparation described in (10), in which the compound enhanced in internal absorption by the conversion to the solid solution is nilvadipine, the additional edible polymer is hydroxypropyl cellulose, and the starch syrup is reducing maltose starch syrup.
- As apparent from the above, the film preparation of the invention is characterized in that it is rapidly dissolved in the oral cavity and can be taken without water, as a dosage form substitutive for a tablet.
- The invention is described in detail below. The invention is the rapidly soluble film preparation in which the drug is allowed to be contained in a film base comprising the edible polymer such as poly (vinylpyrrolidone), hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxyethyl cellulose or ethyl cellulose, and the monosaccharide, the sugar alcohol or the oligosaccharide, and which is easily produced and has no conventional disadvantages as described above.
-
- Fig. 1 is a graph showing the elution rate of a rapidly soluble film preparation of the invention.
-
- The saccharides used in the invention include sugar alcohols such as erythritol, pentitol and hexitol, monosaccharides (aldose and ketose) and oligosaccharides. Specifically, the sugar alcohols include xylitol, mannitol, D-sorbitol and reducing maltose starch syrup, the monosaccharides include glucose and fructose, the oligosaccharides include maltose, lactose and sucrose, and the monosaccharide-oligosaccharides include starch syrup. Reducing maltose starch syrup is particularly preferred. The compounding amount of the saccharides in the film preparation of the present invention is from 1 to 50% by weight, and preferably from 5 to 50% by weight. Less than 1% results in the insufficient rate of dissolution, whereas exceeding 50% raises a problem with regard to the shape retaining property of products, although the rate of dissolution is increased. Many of the saccharides have sweet tastes, and this is advantageous for the film preparations soluble in the mouth. Further, many of them also act as plasticizers, like starch syrup. Accordingly, when they are used, it is not necessary to especially use plasticizers. Of course, the plasticizers may be used as so desired. When sorbitol is used as the saccharide, sorbitol sometimes deposits as crystallites on film surfaces. However, the drug effect and the others are not affected at all.
- There is no particular limitation on the edible polymer which is a component of the film base of the invention, as long as it has film forming ability and is edible. The edible polymers include synthetic polymers, for example, poly(vinylpyrrolidone) (hereinafter described as "PVP"), carboxyvinyl polymers (hereinafter described as "CVPs"), polyvinyl alcohol (hereinafter described as "PVA") and the like, cellulose derivatives, such as hydroxypropyl methyl cellulose (hereinafter described as "HPMC"), hydroxypropyl cellulose (hereinafter described as "HPC"), hydroxyethyl cellulose (hereinafter described as "HEC"), methyl cellulose (hereinafter described as "MC"), ethyl cellulose (hereinafter described as "EC") and the like, and polymers obtained from natural products, for example, sodium alginate, dextran, casein, pullulan and the like. Particularly preferred are PVP and HPC. These substances can be used either alone or as a combination of two or more of them.
- The total compounding amount of the edible polymers in the film preparation is from 20 to 90% by weight, and preferably from 25 to 80% by weight in all.
- For the rapidly soluble film preparations of the invention, aromatics, coloring matter, preservatives, antioxidants, stabilizing agents, surfactants, plasticizers and the like may be properly used as components of the film bases, as so desired, in addition to the above-mentioned substances.
- There is no particular limitation on the drugs used in the invention, as long as they can be orally administered. Specific examples thereof include calcium antagonists such as nilvadipine and nicardipine, β2-stimulants such as procaterol hydrochloride and fenoterol hydrobromide, oral antidiabetic drugs such as glibenclamide, somniferous drugs such as brotizolam and triazolam, β-blockers such as arotinolol hydrochloride and carteolol hydrochloride, therapeutic drugs for the coronary vessels such as nicorandil, anesthetics such as dibucaine hydrochloride, nonsteroidal anti-inflammatory drugs such as diclofenac sodium and indomethacin, and sedatives such as diphenhydramine hydrochloride and scopolamine hydrobromide.
- As the drugs used in the invention, ones having no bitter tastes are suitable. However, even ones having bitter tastes can be used in the invention by masking such as microcapsulation. The compounding amount of the drugs in the film preparation is usually from 1 to 50% by weight, although it varies depending on the properties of the drugs.
- The rapidly soluble film preparations of the invention are produced, for example, by the following method.
- Specified amounts of the edible polymer, saccharide and drug are dissolved in a solvent in which these substances are soluble, for example, ethanol, and the resulting solution is spread on a liner film and dried to obtain a film. The film is cut to a desired size, and hermetically packaged if necessary to provide a product. The dissolution of the drug can be accelerated by heating to about 50 to about 60°C in preparing the solution. Further, when foams are developed in the solution in preparing it, standing overnight or vacuum deaeration is preferably conducted. There is no particular limitation on the solvent used in preparing the solution, as long as it dissolves the respective compounding components. Either a single solvent or a combined solvent may be used. Specifically, the solvents include ethanol, a mixture of ethanol and water, and the like.
- In the invention, it has been found that when the specified edible polymers are used, some kinds of drugs are enhanced in internal absorption thereof. That is to say, for example, when the drug is nilvadipine, the use of poly(vinylpyrrolidone) and/or hydroxypropyl methyl cellulose as the edible polymer(s) enhances the internal absorption. This is considered to be caused by the formation of a good solid solution by nilvadipine with these polymers. In this case, the film preparation can be produced by the use of only poly(vinylpyrrolidone) and/or hydroxypropyl methyl cellulose as the edible polymer(s), but an additional edible polymer can provide a better film preparation. For example, in the case of nilvadipine, hydroxypropyl cellulose is suitably used.
- Specific examples of the drugs forming the solid solutions with the edible polymers include nifedipine, phenytoin, chloramphenicol, griseofulvin, sulfamethizole and the like, as well as nilvadipine.
- The invention is described below in detail with reference to examples. These examples are not to be construed as limiting the invention.
- To a suitable amount of ethanol, 4.0 parts by weight of nilvadipine, 76.0 parts by weight of HPC and 20.0 parts by weight of reducing maltose starch syrup were added and dissolved by stirring. This was spread on a polyester liner film and dried to produce a film having a thickness of about 250 µm. The resulting film was cut to a square, 16 mm each side, thereby obtaining a film preparation rapidly soluble in the oral cavity.
- To a suitable amount of ethanol, 4.0 parts by weight of nilvadipine, 72.0 parts by weight of HPC, 4.0 parts by weight of PVP and 20.0 parts by weight of reducing maltose starch syrup were added and dissolved by stirring. This was spread on a polyester liner film and dried to produce a film having a thickness of about 250 µm. The resulting film was cut to a square, 16 mm each side, thereby obtaining a film preparation rapidly soluble in the oral cavity.
- According to formulations of Table 1, rapidly soluble film preparations were obtained in the same manner as with Example 2.
Name of Component Examples 3 4 5 6 Nilvadipine 4.0 4.0 4.0 4.0 HPC 64.0 56.0 51.0 46.0 PVP 12.0 20.0 20.0 20.0 Reducing Maltose Starch Syrup 20.0 20.0 25.0 30.0 Total 100.0 100.0 100.0 100.0 - To a suitable amount of ethanol, 4.0 parts by weight of nilvadipine, 72.0 parts by weight of HPC, 4.0 parts by weight of HPMC and 20.0 parts by weight of reducing maltose starch syrup were added and dissolved by stirring. This was spread on a polyester liner film and dried to produce a film having a thickness of about 250 µm. The resulting film was cut to a square, 16 mm each side, thereby obtaining a film preparation rapidly soluble in the oral cavity.
- According to formulations of Table 2, rapidly soluble film preparations were obtained in the same manner as with Example 7.
Name of Component Examples 8 9 10 11 12 13 14 Nilvadipine 4.0 4.0 4.0 4.0 4.0 4.0 4.0 HPC 64.0 56.0 51.0 46.0 56.0 56.0 56.0 HPMC 12.0 20.0 20.0 20.0 - - - MC - - - - 20.0 - - EC - - - - - 20.0 - HEC - - - - - - 20.0 Reducing Maltose Starch Syrup 20.0 20.0 25.0 30.0 20.0 20.0 20.0 Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 - To a suitable amount of ethanol, 20.0 parts by weight of nicardipine hydrochloride, 40.0 parts by weight of HPC, 20.0 parts by weight of PVP and 20.0 parts by weight of reducing maltose starch syrup were added and dissolved by stirring. This was spread on a polyester liner film and dried to produce a film having a thickness of about 250 µm. The resulting film was cut to a square, 16 mm each side, thereby obtaining a film preparation rapidly soluble in the oral cavity.
- According to formulations of Table 3, rapidly soluble film preparations were obtained in the same manner as with Example 15.
Name of Component Examples 16 17 18 19 20 21 Fenoterol Hydro-Bromide 5.0 4.0 - - - - Indomethacin - - 2.0 2.0 2.0 2.0 HPC 55.0 56.0 78.0 58.0 78.0 58.0 PVP 20.0 20.0 - - - 20.0 Reducing Maltose Starch Syrup 20.0 - 20.0 40.0 - 20.0 D-Sorbitol - 20.0 - - 20.0 - 100.0 100.0 100.0 100.0 100.0 100.0 - According to formulations of Table 4, rapidly soluble film preparations were obtained in the same manner as with Example 7.
Name of Component Examples 22 23 Nilvadipine 4.0 4.0 PVP 76.0 20.0 EC - 56.0 Reducing Maltose Starch Syrup 20.0 20.0 Total 100.0 100.0 - To a suitable amount of an ethanol-purified water (2:1) mixture, 4.0 parts by weight of nilvadipine, 6.0 parts by weight of HPMC and 20.0 parts by weight of reducing maltose starch syrup were added and dissolved by stirring. This was spread on a polyester separate film and dried to produce a film having a thickness of about 250 µm. The resulting film was cut to a square, 16 mm each side, thereby obtaining a film preparation rapidly soluble in the oral cavity.
- According to formulations of Table 5, rapidly soluble film preparations were obtained in the same manner as with Example 24.
Name of Component Examples 25 26 27 28 Nilvadipine 4.0 4.0 4.0 4.0 HPC - 56.0 - - PVP 20.0 - - - HPMC - 20.0 20.0 20.0 MC 56.0 - 56.0 - EC - - - 56.0 Reducing Maltose Starch Syrup 20.0 20.0 20.0 20.0 Total 100.0 100.0 100.0 100.0 - To a suitable amount of a mixture of ethanol-purified water (2:1), 4.0 parts by weight of nilvadipine, 38.0 parts by weight of PVP, 38.0 parts by weight of HPMC and 20.0 parts by weight of reducing maltose starch syrup were added and dissolved by stirring. This was spread on a polyester liner film and dried to produce a film having a thickness of about 250 µm. The resulting film was cut to a square, 16 mm each side, thereby obtaining a film preparation rapidly soluble in the oral cavity.
- According to formulations of Table 6, rapidly soluble film preparations were obtained in the same manner as with Example 29.
Name of Component Examples 30 31 32 Nilvadipine 4.0 4.0 4.0 HPC 36.0 - - PVP 20.0 20.0 20.0 HPMC 20.0 20.0 20.0 MC - 36.0 - EC - - 36.0 Reducing Maltose Starch Syrup 20.0 20.0 20.0 Total 100.0 100.0 100.0 - To a suitable amount of ethanol, 4.0 parts by weight of nilvadipine, 76.0 parts by weight of HPC and 20.0 parts by weight of PVP were added and dissolved by stirring. This was spread on a polyester liner film and dried to produce a film having a thickness of about 250 µm. The resulting film was cut to a square, 16 mm each side, thereby obtaining a film preparation rapidly soluble in the oral cavity.
- To a suitable amount of ethanol, 2.0 parts by weight of indomethacin and 98.0 parts by weight of HPC were added and dissolved by stirring. This was spread on a polyester liner film and dried to produce a film having a thickness of about 250µm. The resulting film was cut to a square, 16 mm each side, thereby obtaining a film preparation rapidly soluble in the oral cavity.
- In a 100-ml tall beaker, 100 ml of purified water is placed, and stirred (100 rpm) with a stirrer. One piece of sample (16 mm X 16 mm) is placed in a cylindrical stainless steel basket, and put under the water in the beaker. Then, the basket is fixed. After a definite period of time from initiation of the test, 500 µl was sampled, and determined with the HPLC. Results are shown in Fig. 1.
- The film preparations of the invention are very easily produced, have high rapid solubility, are extremely high in practical use, and are suitable for using as film preparations for oral administration.
Claims (11)
- A rapidly soluble film preparation mainly comprising a drug, an edible polymer and a saccharide.
- The rapidly soluble film preparation according to claim 1, in which the content of the drug is from 0.01 to 50% by weight, that of the edible polymer is from 20 to 90% by weight, and that of the saccharide is from 1 to 50% by weight.
- The rapidly soluble film preparation according to claim 1, in which the drug is a compound which can be enhanced in internal absorption by the conversion to a solid solution.
- The rapidly soluble film preparation according to claim 3, in which the compound is nilvadipine.
- The rapidly soluble film preparation according to claim 1, in which the edible polymer is one selected from the group consisting of synthetic polymers, cellulose derivatives and natural polymers.
- The rapidly soluble film preparation according to claim 1 or 5, in which the edible polymer is at least one selected from the group consisting of poly(vinylpyrrolidone), hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxyethyl cellulose and ethyl cellulose.
- The rapidly soluble film preparation according to claim 1 or 2, in which the saccharide is one selected from the group consisting of monosaccharides, sugar alcohols and oligosaccharides.
- The rapidly soluble film preparation according to claim 7, in which the oligosaccharide is starch syrup.
- The rapidly soluble film preparation according to claim 8, in which the starch syrup is reducing maltose starch syrup.
- The rapidly soluble film preparation according to claim 1, in which the drug is a compound which can be enhanced in internal absorption by the conversion to a solid solution, the edible polymer is one or more of poly(vinylpyrrolidone) and hydroxypropyl cellulose, and an additional edible polymer, and the saccharide is starch syrup,
- The rapidly soluble film preparation according to claim 10, in which the compound is nilvadipine, the additional edible polymer is hydroxypropyl cellulose, and the starch syrup is reducing maltose starch syrup.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27596797A JP3460538B2 (en) | 1997-10-08 | 1997-10-08 | Fast dissolving film preparation |
JP27596797 | 1997-10-08 | ||
PCT/JP1998/004499 WO1999017753A1 (en) | 1997-10-08 | 1998-10-06 | Rapidly soluble filmy preparation |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1008343A1 true EP1008343A1 (en) | 2000-06-14 |
EP1008343A4 EP1008343A4 (en) | 2004-12-29 |
EP1008343B1 EP1008343B1 (en) | 2013-02-27 |
Family
ID=17562923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98945623A Expired - Lifetime EP1008343B1 (en) | 1997-10-08 | 1998-10-06 | Rapidly soluble filmy preparation |
Country Status (5)
Country | Link |
---|---|
US (1) | US6906043B2 (en) |
EP (1) | EP1008343B1 (en) |
JP (1) | JP3460538B2 (en) |
ES (1) | ES2402544T3 (en) |
WO (1) | WO1999017753A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1093810A1 (en) * | 1999-10-22 | 2001-04-25 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Fast-dissolving tablet comprising brotizolam |
EP1337148A2 (en) * | 2000-11-30 | 2003-08-27 | Wm. Wrigley Jr. Company | Improved pullulan free edible film compositions and methods of making the same |
WO2003097103A1 (en) * | 2002-05-16 | 2003-11-27 | Kyukyu Pharmaceutical Co.,Ltd. | Quickly soluble film preparations |
EP1370206A1 (en) * | 2001-01-09 | 2003-12-17 | Lavipharm Laboratories, Inc. | Devices for local and systemic delivery of active substances and methods of manufacturing thereof |
US6916463B2 (en) | 2002-09-24 | 2005-07-12 | The Procter & Gamble Company | Oral products having an aesthetic layer |
EP2161021A1 (en) * | 2007-06-07 | 2010-03-10 | Sato Pharmaceutical Co. Ltd. | Medicinal film preparation with rapidly dissolving property and flexibility |
EP2446881A1 (en) | 2003-07-24 | 2012-05-02 | Glaxosmithkline LLC | Orally Dissolving Films |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19646392A1 (en) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery |
US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
ATE238766T1 (en) | 1999-07-02 | 2003-05-15 | Procter & Gamble | COMPOSITIONS FOR RELEASE OF ORAL CARE INGREDIENTS CONTAINING ORGANOSILOXANE RESINS BY USING A REMOVABLE CARRIER STRIP |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US7314716B2 (en) | 1999-11-19 | 2008-01-01 | Mount Sinai School Of Medicine | Gustducin γ subunit materials and methods |
US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
DE10026698A1 (en) * | 2000-05-30 | 2001-12-06 | Basf Ag | Self-emulsifying active ingredient formulation and use of this formulation |
US8268333B2 (en) | 2001-04-24 | 2012-09-18 | Lintec Corporation | Orally administered agent and an orally administered agent/supporting substrate complex |
JP2004043450A (en) * | 2002-05-16 | 2004-02-12 | Kyukyu Yakuhin Kogyo Kk | Quickly soluble filmy preparation |
US6904908B2 (en) * | 2002-05-21 | 2005-06-14 | Trudell Medical International | Visual indicator for an aerosol medication delivery apparatus and system |
US8524200B2 (en) | 2002-09-11 | 2013-09-03 | The Procter & Gamble Company | Tooth whitening products |
US9561182B2 (en) | 2003-08-22 | 2017-02-07 | Cure Pharmaceutical Corporation | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals |
US8999372B2 (en) | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
US20040131662A1 (en) | 2003-11-12 | 2004-07-08 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US20040191302A1 (en) | 2003-03-28 | 2004-09-30 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
JP2003146878A (en) * | 2002-11-22 | 2003-05-21 | Sawai Pharmaceutical Co Ltd | Readily soluble solid preparation containing nilvadipine, and method for producing the same |
CA2520380A1 (en) * | 2003-03-26 | 2004-10-14 | The Procter & Gamble Company | Rapidly dissolving edible film compositions with cellulose film forming polymers |
JP4982669B2 (en) * | 2003-06-17 | 2012-07-25 | 株式会社林原 | Film-like sweetness composition |
DE10338544B4 (en) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccal formulations of galanthamine and their applications |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
ES2426990T3 (en) * | 2003-10-24 | 2013-10-28 | Adhesives Research, Inc. | Disposable films for diagnostic devices |
CN102669810B (en) | 2003-11-07 | 2014-11-05 | 美国无烟烟草有限责任公司 | Tobacco compositions |
US8627828B2 (en) | 2003-11-07 | 2014-01-14 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
AU2005204391A1 (en) * | 2004-01-14 | 2005-07-28 | Lavipharm Laboratories, Inc. | Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid |
US20050208108A1 (en) * | 2004-03-19 | 2005-09-22 | Jannusch Leonard C | Thermoplastic films and methods for making |
US7785619B2 (en) | 2004-04-08 | 2010-08-31 | Micro Nutrient, Llc | Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens |
US7850987B2 (en) | 2004-04-08 | 2010-12-14 | Micronutrient, Llc | Nutrient composition(s) and system(s) for individualized, responsive dosing regimens |
CA2606724A1 (en) * | 2005-05-03 | 2006-11-09 | Innozen, Inc. | Edible film for transmucosal delivery of nutritional supplements |
CN101808667B (en) | 2007-09-28 | 2012-11-21 | 琳得科株式会社 | Medicinal preparation for oral administration |
JP5590891B2 (en) | 2007-12-06 | 2014-09-17 | リンテック株式会社 | Edible film |
US20110054043A1 (en) | 2008-04-15 | 2011-03-03 | Takeshi Funaki | Film composition |
TWI441659B (en) | 2008-09-29 | 2014-06-21 | Lintec Corp | Oral administration |
JP2010158173A (en) * | 2009-01-06 | 2010-07-22 | Lintec Corp | Edible film, edible film composition, and method for producing edible film laminated body |
JP5674480B2 (en) * | 2009-01-29 | 2015-02-25 | 日東電工株式会社 | Intraoral film-form base and preparation |
JP5379499B2 (en) * | 2009-01-29 | 2013-12-25 | リンテック株式会社 | Swallow package and edible film assembly |
WO2010086989A1 (en) | 2009-01-29 | 2010-08-05 | 日東電工株式会社 | Intraoral film-shaped base and preparation |
TWI455733B (en) | 2009-03-30 | 2014-10-11 | Toray Industries | A coating tablet collapsible in the oral cavity |
JP2011016781A (en) * | 2009-07-10 | 2011-01-27 | Tsukioka:Kk | Film-like formulation |
US9868974B2 (en) | 2009-07-27 | 2018-01-16 | SureSensors Ltd. | Sensor devices |
JP5497358B2 (en) * | 2009-07-28 | 2014-05-21 | リンテック株式会社 | Edible laminated film and method for producing the same |
US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
US20110136815A1 (en) * | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
JP5588688B2 (en) * | 2010-01-28 | 2014-09-10 | 日東電工株式会社 | Film-form preparation |
JP5466028B2 (en) * | 2010-02-03 | 2014-04-09 | リンテック株式会社 | Edible sheet and food holding sheet |
JP5751868B2 (en) | 2010-03-30 | 2015-07-22 | 日東電工株式会社 | Film-form preparation and method for producing the same |
US10238684B2 (en) | 2010-11-18 | 2019-03-26 | Foundational Biosystems, Llc | Micro- and nano-quantity sleep enhancing nutrient composition and method of enhancing central nervous system protein clearance using same |
EP2665465A1 (en) | 2011-01-17 | 2013-11-27 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
WO2013054582A1 (en) | 2011-10-14 | 2013-04-18 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
JP5841433B2 (en) | 2012-01-11 | 2016-01-13 | 日東電工株式会社 | Intraoral film-form base and preparation |
WO2013121663A1 (en) | 2012-02-14 | 2013-08-22 | 救急薬品工業株式会社 | Intraorally dissolving film preparation |
EP3659630B1 (en) | 2013-03-15 | 2023-12-27 | Smith & Nephew, Inc. | Dissolvable gel-forming film for delivery of active agents |
JP6482552B2 (en) * | 2013-07-31 | 2019-03-13 | インテルジェンクス・コーポレイションIntelGenx Corp. | Oral film dosage form that is immediately wettable without surfactants and polyhydric alcohols |
US20160296463A1 (en) * | 2013-11-11 | 2016-10-13 | Impax Laboratories, Inc. | Rapidly disintegrating formulations and methods thereof |
JPWO2016163403A1 (en) * | 2015-04-07 | 2018-02-01 | ニプロ株式会社 | Oral film formulation |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN142428B (en) * | 1974-07-05 | 1977-07-09 | Schering Ag | |
US4136162A (en) * | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
JPS5154917A (en) * | 1974-11-01 | 1976-05-14 | Toppan Printing Co Ltd | SEIZAIHOHO |
JPS6185315A (en) * | 1984-10-04 | 1986-04-30 | Teikoku Seiyaku Kk | Sheet-like preparation |
JPS63501794A (en) * | 1985-10-09 | 1988-07-21 | デジテイン アルツナイミツテル ゲ−エムベ−ハ− | Methods for providing pharmaceutically active substances, reagents, and other active substances or for producing dosage forms |
US4855326A (en) * | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
JPH02124945A (en) * | 1988-07-27 | 1990-05-14 | Kuraray Co Ltd | Water-soluble film |
JPH02182154A (en) * | 1988-12-30 | 1990-07-16 | Tsutomu Yokoi | Edible film and wound-coating film |
US6106856A (en) * | 1994-03-09 | 2000-08-22 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Transdermal delivery of calcium channel blockers, such as nifedipine |
US6294202B1 (en) * | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
JP2791317B2 (en) * | 1995-12-26 | 1998-08-27 | 株式会社三和化学研究所 | Multilayer film preparation |
JP2935343B2 (en) * | 1996-03-04 | 1999-08-16 | 花王株式会社 | Sheet pack |
US5800832A (en) * | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
JPH10179045A (en) * | 1996-12-25 | 1998-07-07 | Osaka Kagaku Gokin Kk | Sheet-like edible molding |
-
1997
- 1997-10-08 JP JP27596797A patent/JP3460538B2/en not_active Expired - Fee Related
-
1998
- 1998-10-06 ES ES98945623T patent/ES2402544T3/en not_active Expired - Lifetime
- 1998-10-06 EP EP98945623A patent/EP1008343B1/en not_active Expired - Lifetime
- 1998-10-06 US US09/529,234 patent/US6906043B2/en not_active Expired - Fee Related
- 1998-10-06 WO PCT/JP1998/004499 patent/WO1999017753A1/en active Application Filing
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO9917753A1 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1093810A1 (en) * | 1999-10-22 | 2001-04-25 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Fast-dissolving tablet comprising brotizolam |
EP1337148A4 (en) * | 2000-11-30 | 2005-03-16 | Wrigley W M Jun Co | Improved pullulan free edible film compositions and methods of making the same |
EP1337148A2 (en) * | 2000-11-30 | 2003-08-27 | Wm. Wrigley Jr. Company | Improved pullulan free edible film compositions and methods of making the same |
EP1370206A4 (en) * | 2001-01-09 | 2006-04-05 | Lavipharm Lab Inc | Devices for local and systemic delivery of active substances and methods of manufacturing thereof |
EP1370206A1 (en) * | 2001-01-09 | 2003-12-17 | Lavipharm Laboratories, Inc. | Devices for local and systemic delivery of active substances and methods of manufacturing thereof |
WO2003097103A1 (en) * | 2002-05-16 | 2003-11-27 | Kyukyu Pharmaceutical Co.,Ltd. | Quickly soluble film preparations |
AU2003235294B2 (en) * | 2002-05-16 | 2008-04-17 | Kyukyu Pharmaceutical Co., Ltd. | Quickly soluble film preparations |
CN100396332C (en) * | 2002-05-16 | 2008-06-25 | 救急药品工业株式会社 | Quickly soluble film preparations |
US6916463B2 (en) | 2002-09-24 | 2005-07-12 | The Procter & Gamble Company | Oral products having an aesthetic layer |
EP2446881A1 (en) | 2003-07-24 | 2012-05-02 | Glaxosmithkline LLC | Orally Dissolving Films |
EP2161021A1 (en) * | 2007-06-07 | 2010-03-10 | Sato Pharmaceutical Co. Ltd. | Medicinal film preparation with rapidly dissolving property and flexibility |
EP2161021A4 (en) * | 2007-06-07 | 2013-12-11 | Sato Pharma | Medicinal film preparation with rapidly dissolving property and flexibility |
US9125836B2 (en) | 2007-06-07 | 2015-09-08 | Sato Pharmaceutical Co., Ltd. | Film preparation with rapidly dissolving property and flexibility |
Also Published As
Publication number | Publication date |
---|---|
WO1999017753A1 (en) | 1999-04-15 |
EP1008343B1 (en) | 2013-02-27 |
US20030099690A1 (en) | 2003-05-29 |
JP3460538B2 (en) | 2003-10-27 |
EP1008343A4 (en) | 2004-12-29 |
ES2402544T3 (en) | 2013-05-06 |
JPH11116469A (en) | 1999-04-27 |
US6906043B2 (en) | 2005-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6906043B2 (en) | Rapidly soluble film preparation | |
EP1504765B1 (en) | Quickly soluble film preparations | |
EP0804170B1 (en) | Method for making freeze dried drug dosage forms | |
US6187336B1 (en) | Process for producing a solid which is rapidly soluble in the oral cavity | |
EP2233129B1 (en) | Oral cavity disintegrating tablet and method of producing the same | |
KR960014868B1 (en) | Moderated spun fibrous medicinal dosage unit and method of manufacture thereof | |
KR100258223B1 (en) | Fast dissolving tablet and its production | |
US5629003A (en) | Rapidly disintegrating sheet-like presentations of multiple dosage units | |
RU2437648C2 (en) | Foamed lozenge containing grafted copolymer of polyvinyl alcohol and polyethylene glycol | |
JP5213446B2 (en) | Pharmaceutical composition comprising diclofenac | |
RU2445977C2 (en) | Water-soluble films containing low-viscosity alginates | |
RU2182445C2 (en) | Compressed form (variants) and agent improving its compressibility | |
WO2001089485A1 (en) | Rapidly disintegrating tablet and process for the manufacture thereof | |
RU2273472C2 (en) | Medicinal composition decomposing in mouth cavity rapidly and method for its preparing | |
WO2004073632A2 (en) | Rapid absorption selective 5-ht agonist formulations | |
Nandy et al. | An overview on fast dissolving drug delivery system | |
RU2056835C1 (en) | Method of preparing soluble medicinal agent | |
CN105193772A (en) | Saxagliptin oral membrane and preparation method thereof | |
WO2003086361A1 (en) | Rapidly dispersing solid oral compositions | |
JP2000512303A (en) | Quickly disintegrating dosage form marking | |
EP2445486B1 (en) | Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen | |
Kumar et al. | Mouth Dissolving Tablets: A Modern Approach to Delivery of Drug | |
JP4358919B2 (en) | Method for producing intraoral rapidly soluble solid | |
Bhakare et al. | Deep Insights into the Developmental Progress of Orally Disintegrating Tablet Formulation, Techniques, and Products: A Comprehensive Review | |
Guleri et al. | Medicinal Chemistry & Analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000328 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): CH DE ES FR GB IT LI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041112 |
|
17Q | First examination report despatched |
Effective date: 20061211 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SAWAI, YOSHIHIRO Inventor name: FURUSAWA, KAZUYOSHI Inventor name: AWAMURA, TSUTOMU |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: KYUKYU PHARMACEUTICAL CO., LTD. |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): CH DE ES FR GB IT LI |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 69842966 Country of ref document: DE Effective date: 20130425 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2402544 Country of ref document: ES Kind code of ref document: T3 Effective date: 20130506 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOHEST AG, CH |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20131128 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 69842966 Country of ref document: DE Effective date: 20131128 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH) |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20141107 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20131007 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20161025 Year of fee payment: 19 Ref country code: DE Payment date: 20161028 Year of fee payment: 19 Ref country code: FR Payment date: 20161025 Year of fee payment: 19 Ref country code: GB Payment date: 20161025 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20161025 Year of fee payment: 19 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69842966 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20171006 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20180629 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171006 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171031 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180501 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171006 |